EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond lipids: a precision prevention blueprint for China's residual risk

Ming Chi, Taoming Qian, Jirong Zhang, Weiqing Qiao, Juan Jin

Frontiers in Medicine · 17.08.2026 · 13

DOI: 10.3389/fmed.2026.1929544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 17.08.2026. Verfasst von Ming Chi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite achieving guideline-recommended lipid levels, patients with atherosclerotic cardiovascular disease (ASCVD) retain substantial residual risk arising from heterogeneous biological pathways, including persistent inflammation and genetically determined atherogenic susceptibility. High-sensitivity C-reactive protein (hs-CRP) provides a pragmatic measure of potentially modifiable inflammatory activity, whereas lipoprotein(a) [Lp(a)] identifies relatively stable, genetically mediated risk that is not adequately captured by standard lipid panels. The 2025 American College of Cardiology Scientific Statement highlights hs-CRP as a clinically useful inflammatory-risk marker and supports consideration of low-dose colchicine in appropriately selected secondary-prevention patients. The 2026 ACC/AHA multisociety dyslipidemia guideline further provides a Class I recommendation for once-in-a-lifetime Lp(a) measurement, creating a complementary multimodal framework for residual-risk assessment. In China, where cardiovascular disease accounts for a substantial proportion of deaths and the national cardiovascular burden continues to increase, implementation of this framework remains limited. Routine hs-CRP measurement is uncommon, cardiovascular use of colchicine remains negligible, and Lp(a) testing is still concentrated in selected tertiary centers. Emerging East Asian data and a recent Chinese expert advisory suggest that an hs-CRP threshold of approximately 1.0 mg/L may improve inflammatory-risk discrimination in Chinese patients with coronary artery disease; however, this threshold should not yet be interpreted as a stand-alone treatment threshold for colchicine. In this perspective, we compare international recommendations with current Chinese practice, analyze barriers related to infrastructure, safety, education, standardization, and evidence localization, and propose a multimodal implementation framework. Short-term priorities include once-in-a-lifetime Lp(a) measurement, context-specific hs-CRP assessment, intensified management of modifiable atherosclerotic risk factors, and carefully selected use of low-dose colchicine in secondary prevention. Elevated Lp(a) should prompt comprehensive risk-factor intensification and, when appropriate, family-based evaluation, but should not by itself constitute an indication for colchicine. Medium- and long-term priorities include pragmatic trials, real-world registries, assay standardization, cost-effectiveness studies, and policy initiatives to integrate residual-risk assessment into Chinese cardiovascular prevention pathways.

Schlagwörter

Stichwörter der Autor:innen

Chinese cardiovascular diseasecolchicinehigh-sensitivity C-reactive proteinlipoprotein(a)precision preventionresidual inflammatory riskresidual risksecondary prevention

Autor:innen und Institutionen

  • Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
  • Department of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Cardiovascular Department, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.

Zitieren

APA

Chi, M., Qian, T., Zhang, J., Qiao, W., & Jin, J. (2026). Beyond lipids: a precision prevention blueprint for China's residual risk. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1929544

Vancouver

Chi M, Qian T, Zhang J, Qiao W, Jin J. Beyond lipids: a precision prevention blueprint for China's residual risk. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1929544

BibTeX
@article{Chi2026,
  author = {Chi, Ming and Qian, Taoming and Zhang, Jirong and Qiao, Weiqing and Jin, Juan},
  title = {Beyond lipids: a precision prevention blueprint for China's residual risk},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1929544}
}
Kostenlos starten →